MeiraGTx Holdings plc, a New York-based clinical stage gene therapy company, is making significant strides in developing treatments for patients suffering from severe diseases. With a focus on addressing ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, MeiraGTx Holdings plc is also researching therapies for neurodegenerative diseases and xerostomia. The company has several programs in clinical development, including Phase I/II clinical stage initiatives for achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials targeting radiation-induced xerostomia; and a Parkinson's program that has completed a Phase II trial. Furthermore, MeiraGTx Holdings plc has established a research collaboration agreement with Janssen Pharmaceuticals, Inc. focused on the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. Since its inception in 2015, MeiraGTx Holdings plc has cemented its position as a progressive force within the gene therapy space.
MeiraGTx's ticker is MGTX
The company's shares trade on the NASDAQ stock exchange
They are based in New York City, New York
There are 51-200 employees working at MeiraGTx
It is https://meiragtx.com/
MeiraGTx is in the Healthcare sector
MeiraGTx is in the Biotechnology industry
The following five companies are MeiraGTx's industry peers:
- SpringWorks Therapeutics, Inc.